| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sierra Oncology Inc (NASDAQ: SRRA)
SRRA Technical Analysis
5
| As on 1st Jul 2022 SRRA SHARE Price closed @ 54.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 19.02 & Strong Buy for SHORT-TERM with Stoploss of 15.89 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SRRASHARE Price
| Open | 54.99 | Change | Price | % |
| High | 54.99 | 1 Day | 0.00 | 0.00 |
| Low | 54.99 | 1 Week | 0.05 | 0.09 |
| Close | 54.99 | 1 Month | 0.34 | 0.62 |
| Volume | N/A | 1 Year | 38.94 | 242.62 |
| 52 Week High 54.97 | 52 Week Low 13.94 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SRRA Daily Charts |
SRRA Intraday Charts |
Whats New @ Bazaartrend |
SRRA Free Analysis |
|
|
SRRA Important Levels Intraday
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
| RESISTANCE | 54.99 |
SRRA Forecast April 2024
| 4th UP Forecast | 62.35 |
| 3rd UP Forecast | 59.99 |
| 2nd UP Forecast | 58.53 |
| 1st UP Forecast | 57.07 |
| 1st DOWN Forecast | 52.91 |
| 2nd DOWN Forecast | 51.45 |
| 3rd DOWN Forecast | 49.99 |
| 4th DOWN Forecast | 47.63 |
SRRA Weekly Forecast
| 4th UP Forecast | 58.84 |
| 3rd UP Forecast | 57.61 |
| 2nd UP Forecast | 56.84 |
| 1st UP Forecast | 56.08 |
| 1st DOWN Forecast | 53.90 |
| 2nd DOWN Forecast | 53.14 |
| 3rd DOWN Forecast | 52.37 |
| 4th DOWN Forecast | 51.14 |
SRRA Forecast2024
| 4th UP Forecast | 134.98 |
| 3rd UP Forecast | 109.33 |
| 2nd UP Forecast | 93.47 |
| 1st UP Forecast | 77.61 |
| 1st DOWN Forecast | 32.37 |
| 2nd DOWN Forecast | 16.51 |
| 3rd DOWN Forecast | 0.65 |
| 4th DOWN Forecast | -25 |
Sierra Oncology Inc ( NASDAQ USA Symbol : SRRA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SRRA Business Profile
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California. Address: 1820 Gateway Drive, San Mateo, CA, United States, 94404
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service